Key Market Indicator:
F&G: 62
25.194,00 NASDAQ · 48.676,49 DOW · 6.824,25 S&P · 4.729,20 Gold · 63,43 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
SE0006091997
Filter zurücksetzen
© PR Newswire
02.04.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia publishes the Annual Report for 2024
Article
News Preview
LUND, Sweden, April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published. The annual report can be downloaded in pdf format and is available on Immunovia's website. For more information, please contact: Jeff Borcherding CEO and President jeff.borcherding@immunovia.com   Immunovia in brie...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
The exercise period for warrants series TO 3 begins today
Article
News Preview
LUND, Sweden, April 1, 2025 /PRNewswire/ -- Today, 1 April 2025, the exercise period for warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 15 April 2025. Summarized terms for the warrants of series TO 3 Structure: One (1) warrant series TO 3 entitles the ho...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 3
Article
News Preview
LUND, Sweden, March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in t...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
24.03.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
21.03.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
Article
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET. Jeff Borch...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of st...
Themefolio
Profiler
Peergroup
© PR Newswire
03.03.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference
Article
News Preview
LUND, Sweden, March 3, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week® (DDW) 2025 conference, taking place May 5, 2025. The CLARITI study w...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia Publishes Full Year Report for 2024
Article
News Preview
LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --  October-December 2024 Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc.Operating losses were -30...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia initiates search for a new CFO to support commercialization in the USA
Article
News Preview
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that it will be hiring a new Chief Financial Officer (CFO) as its focus turns to the US market. As Immunovia transitions to commercializing its test in the second half of 2025, the company's financial lead...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Invitation to Immunovia's Q4 presentation
Article
News Preview
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ -- Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com. Jeff Borcherding, CEO and P...
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
Article
News Preview
LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to 261,908,863. For further information, please contactJeff Bo...
Themefolio
Profiler
Peergroup
© PR Newswire
31.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
Article
News Preview
LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to 261,908,863. For further information, please contact:Jeff B...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia AB announces outcome of exercise of warrants series TO 2
Article
News Preview
LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 perc...
Themefolio
Profiler
Peergroup
© PR Newswire
20.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia AB announces outcome of exercise of warrants series TO 2
Article
News Preview
LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 perc...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
Article
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.  According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
Article
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.  According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
Article
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025. Summarized terms for the...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
The exercise period for warrants of series TO 2 beings today: Immunovia AB
Article
News Preview
LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025. Summarized terms for the...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
Article
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© PR Newswire
28.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
Article
News Preview
LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading i...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia discovery study published in top protein research journal
Article
News Preview
LUND, Sweden, Dec. 20, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the...
Themefolio
Profiler
Peergroup
© PR Newswire
19.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding
Article
News Preview
LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities that lie ahead in 2025. In 2024 we rapidly delivered multiple key milestones to put Immunovia on a path to success As 2024 began, we had recently completed a significant transformation...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
Article
News Preview
LUND, Sweden, Dec. 18, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced its CEO and board members intend to exercise all TO2 warrants they received in the company's rights issue that was announced on May 20, 2024. Immunovia CEO Jeff Borcherding, one of the company's largest sha...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, Dec. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow up, Immunovia will host a webcast on Tuesday, December 17 at 3 pm CET. Jeff Borcherdi...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces financial calendar for financial year 2025/2026
Article
News Preview
LUND, Sweden, Dec. 11, 2024 /PRNewswire/ -- Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2025/2026. Year-End 2024 Report            February 25, 2025  Q1 Report, 2025                     May 14, 2025  Q2 Report, 2025     ...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer
Article
News Preview
LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC). In the study of over 1,000 pa...
Themefolio
Profiler
Peergroup
© PR Newswire
28.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia to present at the Redeye Technology & Life Science Day
Article
News Preview
LUND, Sweden, Nov. 28, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3, hosted by Redeye. Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking wo...
Themefolio
Profiler
Peergroup
© PR Newswire
27.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia Publishes Interim Report for January-September 2024
Article
News Preview
LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --  July-September 2024 Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1 MSEK (-38.6).Earnings per share before and after dilution were -0.73 SEK (-0.91).Cash flow from operating activities amounted to -21.2 MSEK (-35.6).Cash and cash equi...
Themefolio
Profiler
Peergroup
© PR Newswire
27.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia Publishes Interim Report for January-September 2024
Article
News Preview
LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --  July-September 2024 Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1 MSEK (-38.6).Earnings per share before and after dilution were -0.73 SEK (-0.91).Cash flow from operating activities amounted to -21.2 MSEK (-35.6).Cash and cash equi...
Themefolio
Profiler
Peergroup
© PR Newswire
15.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas--Inherited Gastrointestinal Cancers
Article
News Preview
PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company's next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC)....
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Invitation to Immunovia's Q3 presentation
Article
News Preview
LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding, CEO an...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Invitation to Immunovia's Q3 presentation
Article
News Preview
LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding, CEO an...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
Article
News Preview
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ --  Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic can...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
Article
News Preview
SAN DIEGO, Nov. 7, 2024 /PRNewswire/ --  Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic can...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
Article
News Preview
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfull...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
Article
News Preview
LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfull...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia completes analytical validation of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia completes analytical validation of its next-generation pancreatic cancer test
Article
News Preview
LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
Article
News Preview
LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to un...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Change in number of shares and votes in Immunovia AB (publ)
Article
News Preview
LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to un...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Article
News Preview
LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027). Immunovia shared results from the model development study of its...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2024
ISIN: SE0006091997
Immunovia AB (publ)
IMMNOV
LISTED
STO
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Article
News Preview
LUND, Sweden, Sept. 16, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027). Immunovia shared results from the model development study of its...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Tuesday, 20.01.2026, Calendar Week 04, 20th day of the year, 345 days remaining until EoY.